A 4-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-Induced Weight Gain in Healthy Male Volunteers

Trial Profile

A 4-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-Induced Weight Gain in Healthy Male Volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2012

At a glance

  • Drugs Mifepristone (Primary) ; Risperidone
  • Indications Schizophrenia; Weight gain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 28 Jun 2009 Results presented at the 9th World Congress of Biological Psychiatry 2009.
    • 05 Jun 2009 The primary endpoint 'Bodyweight' has been Met according to the result published as an abstract in the proceedings of the 69th Annual Scientific Sessions of the American Diabetes Association.
    • 02 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top